Curis
Curis is a clinical-stage biotechnology company developing orally administered small-molecule therapeutics and immune-modulatory agents for oncology. The company conducts early-phase (Phase 1/2) trials, including dose-escalation and expansion cohorts, across hematologic malignancies and selected solid tumors. Clinical programs integrate translational biomarker and PK/PD assessments and run as multicenter studies in the United States and multiple international locations.
Industries
Nr. of Employees
small (1-50)
Patents
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US-12403142-B2
View Details
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US-12403142-B2
View DetailsProducts
Clinical‑stage oral IRAK4/FLT3‑targeting kinase inhibitor (hematologic malignancies and selected solid tumors)
A clinical‑stage orally administered small‑molecule kinase inhibitor being developed for IRAK4‑driven hematologic malignancies and other cancers; evaluated in multiple Phase 1/2 studies including monotherapy and combination regimens.
Clinical‑stage HDAC/PI3K inhibitor program (MYC‑altered cancers)
A clinical‑stage program combining HDAC and PI3K inhibitory activity being developed for MYC‑altered cancers and evaluated in early‑phase studies.
Clinical‑stage immune‑modulatory programs (PD‑1/PD‑L1 and other checkpoint pathways)
Early‑stage immune checkpoint and immune‑modulatory programs targeting PD‑1/PD‑L1 and other checkpoint pathways being evaluated in proof‑of‑principle or early clinical activity studies.
Emavusertib
An IRAK4 inhibitor targeted therapy being developed for IRAK4-driven leukemia (AML/MDS) and lymphoma (NHL, CLL, WM).
AU-2807
An IRAK-4 small molecule inhibitor profiled for kinase inhibition, in-vivo efficacy in a rat CIA model, and pharmacokinetics.
AU-6686
An IRAK-4 small molecule inhibitor demonstrating potent target engagement and inhibition of IRAK-1 phosphorylation.
Clinical‑stage oral IRAK4/FLT3‑targeting kinase inhibitor (hematologic malignancies and selected solid tumors)
A clinical‑stage orally administered small‑molecule kinase inhibitor being developed for IRAK4‑driven hematologic malignancies and other cancers; evaluated in multiple Phase 1/2 studies including monotherapy and combination regimens.
Clinical‑stage HDAC/PI3K inhibitor program (MYC‑altered cancers)
A clinical‑stage program combining HDAC and PI3K inhibitory activity being developed for MYC‑altered cancers and evaluated in early‑phase studies.
Clinical‑stage immune‑modulatory programs (PD‑1/PD‑L1 and other checkpoint pathways)
Early‑stage immune checkpoint and immune‑modulatory programs targeting PD‑1/PD‑L1 and other checkpoint pathways being evaluated in proof‑of‑principle or early clinical activity studies.
Emavusertib
An IRAK4 inhibitor targeted therapy being developed for IRAK4-driven leukemia (AML/MDS) and lymphoma (NHL, CLL, WM).
AU-2807
An IRAK-4 small molecule inhibitor profiled for kinase inhibition, in-vivo efficacy in a rat CIA model, and pharmacokinetics.
AU-6686
An IRAK-4 small molecule inhibitor demonstrating potent target engagement and inhibition of IRAK-1 phosphorylation.
Expertise Areas
- Clinical trial management
- Phase 1/2 oncology development
- Oncology small‑molecule drug development
- Combination therapy development (targeted + chemo/immunotherapy)
Key Technologies
- Oral small‑molecule kinase inhibitors (IRAK4, FLT3)
- Model‑assisted dose‑escalation methods (e.g., BOIN)
- Pharmacokinetic and pharmacodynamic assays
- Tumor biopsy–based translational assays
News & Updates
Press release announcing the pricing of a public offering.
Press release reporting dosing of the first five patients in a CLL clinical study.
Press release summarizing a positive update for the company's IRAK4‑targeting clinical program.
Corporate presentation and investor slide deck.
Press release announcing the pricing of a public offering.
Press release reporting dosing of the first five patients in a CLL clinical study.
Press release summarizing a positive update for the company's IRAK4‑targeting clinical program.
Corporate presentation and investor slide deck.